How many 8-K filings has Immuneering Corp filed?

Immuneering Corp (IMRX) has 12 8-K (Current Event Report) filings on record, spanning Feb 2024 to Sep 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Immuneering Corp 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Immuneering Corp 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Immuneering Corp (IMRX) — 8-K Filings

All 8-K filings from Immuneering Corp. Browse 12 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (12)

Immuneering Corp. Signs Material Definitive Agreement — Sep 25, 2025 Risk: medium
Immuneering Corp. announced on September 24, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with its prin
Immuneering Corp Files 8-K: Material Agreement & Equity Sales — Sep 24, 2025 Risk: medium
On September 24, 2025, Immuneering Corporation entered into a material definitive agreement. The company also reported on unregistered sales of equity securitie
Immuneering Corp. Reports Material Definitive Agreement — Aug 25, 2025 Risk: medium
On August 21, 2025, Immuneering Corp. entered into a material definitive agreement related to unregistered sales of equity securities. The company, located at 2
Pfizer to Acquire Immuneering for $625M — Jun 17, 2025 Risk: medium
Immuneering Corp. announced on June 17, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. The transaction is valued at approxi
Immuneering Corp. Files 8-K on Shareholder Vote Matters — Jun 16, 2025 Risk: low
Immuneering Corp. filed an 8-K on June 16, 2025, reporting on a matter submitted to a vote of its security holders on June 13, 2025. The filing details the comp
Pfizer to Acquire Immuneering Corp. — Jan 13, 2025 Risk: medium
Immuneering Corp. announced on January 13, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. The transaction is expected to cl
Pfizer to Acquire Immuneering Corp for $635M — Jan 7, 2025 Risk: medium
Immuneering Corp. announced on January 7, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. for $63.00 per share in cash, repr
Pfizer to Acquire Immuneering Corp. — Sep 12, 2024 Risk: medium
Immuneering Corp. announced on September 12, 2024, that it has entered into a definitive agreement to be acquired by Pfizer Inc. The transaction is expected to
Immuneering Corp. Files 8-K on Shareholder Vote Matters — Jun 13, 2024 Risk: low
Immuneering Corp. filed an 8-K on June 13, 2024, reporting on matters submitted to a vote of security holders as of June 12, 2024. The filing details the compan
Immuneering Corp Appoints New CMO, Elects Director — May 23, 2024 Risk: medium
Immuneering Corp. announced on May 21, 2024, the appointment of Dr. Sarah E. Bloch as Chief Medical Officer and the election of Ms. Jennifer L. Jones to its Boa
Immuneering Corp Appoints New CMO and CSO — Mar 14, 2024 Risk: medium
Immuneering Corp. announced on March 11, 2024, the appointment of Dr. Sarah Hough as Chief Medical Officer and Dr. David L. Brown as Chief Scientific Officer. T
Immuneering 8-K: Bylaw/Charter Amendment, Nasdaq Listing Confirmed — Feb 2, 2024
Immuneering Corporation filed an 8-K on February 2, 2024, reporting an event on February 1, 2024, related to amendments to its Articles of Incorporation or Byla

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX